Marksans Pharma Limited — Updates, 30-06-2025: Press Release

Marksans Pharma’s US subsidiary, Time-Cap Laboratories, has received the Establishment Inspection Report from the USFDA following a recent cGMP inspection. This signals ongoing regulatory compliance at its manufacturing facility in New York. No operational disruption or financial impact was indicated. The firm continues focusing on global generic formulations across therapies like CVS, CNS, and anti-diabetic segments.